miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia

miR-15a 靶向慢性粒细胞白血病中的 HSP90 辅助分子伴侣 Morgana

阅读:7
作者:Pietro Poggio, Stefania Rocca, Federica Fusella, Roberta Ferretti, Ugo Ala, Flora D'Anna, Emilia Giugliano, Cristina Panuzzo, Diletta Fontana, Valeria Palumbo, Giovanna Carrà, Daniela Taverna, Carlo Gambacorti-Passerini, Giuseppe Saglio, Carmen Fava, Rocco Piazza, Alessandro Morotti, Francesca Orso,

Abstract

Morgana is a ubiquitous HSP90 co-chaperone protein coded by the CHORDC1 gene. Morgana heterozygous mice develop with age a myeloid malignancy resembling human atypical myeloid leukemia (aCML), now renamed MDS/MPN with neutrophilia. Patients affected by this pathology exhibit low Morgana levels in the bone marrow (BM), suggesting that Morgana downregulation plays a causative role in the human malignancy. A decrease in Morgana expression levels is also evident in the BM of a subgroup of Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) patients showing resistance or an incomplete response to imatinib. Despite the relevance of these data, the mechanism through which Morgana expression is downregulated in patients' bone marrow remains unclear. In this study, we investigated the possibility that Morgana expression is regulated by miRNAs and we demonstrated that Morgana is under the control of four miRNAs (miR-15a/b and miR-26a/b) and that miR-15a may account for Morgana downregulation in CML patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。